The adjustment comes after a reassessment of the anticipated performance of Biogen's Alzheimer's treatment, Leqembi. The launch of Leqembi has not met the expectations set by analysts, leading to ...

Eisai Co (ESAIY) and Biogen Inc. (BIIB) announced that the latest findings for lecanemab-irmb, an anti-amyloid beta protofibril* antibody for the treatment of early Alzheimer’s disease, were ...

STOCKHOLM, Oct. 30, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the third quarter 2024 ...

The company also raised its full-year profit guidance. Sales of its breakthrough Alzheimer's drug, Leqembi, along with new rare disease and depression treatments, helped offset a year-over-year ...

NEW HYDE PARK, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- CareMed, a leading independent Specialty Pharmacy, has been selected by Eisai to be in the pharmacy network for Leqembi® (lecanemab-irmb).

According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...

It is the second Alzheimer’s drug to receive such a mixed reception within months. In August, the U.K. regulator authorized Leqembi while the same watchdog agency issued draft guidance recommending ...

Early last year, the Food and Drug Administration approved Eisai’s Alzheimer’s drug, marketed as Leqembi, saying its modest benefit — a slight slowing of cognitive decline for a handful of ...

Japan’s Eisai and U.S.-based Biogen are set to launch their jointly developed Alzheimer’s drug, Leqembi (ingredient name: lecanemab), in Korea next month, but concerns about its safety continue to be ...